Clinical Features and Analysis in Pituitary Stalk Interruption Syndrome

Table 4

Clinical characteristics in PSIS patients of normal height (with no history of growth hormone therapy).

Parameters	Patient 1	Patient 2	Patient 3	Patient 4	Normal range
Age at diagnosis (year)	27	11	30	15
Gender	Male	Male	Male	Female
Height (cm)	174	170	164	172
BMI (kg/m^2)	24.3	20	14.35	22.3
Waist circumference (cm)	88	71	64	75
WHR	0.9	0.77	0.85	0.8
SBP (mmHg)	125	92	117	131
DBP (mmHg)	66	61	78	67
Birth history	Dystocia	No special situation	Resuscitation in neonatal period	Dystocia
IGF-1(ng/mL)	<25	36.7	<25	58.02
IGF-1<-2 SDS	Yes	Yes	Yes	Yes
Testosterone (ng/mL)	<0.13	0.28	0.37	<0.13	Male 1.58–8.77
					Female (follicular phase) 0.13-1.30
Estradiol (pg/mL)	<10	<10	<10	<10	Male <44
					Female (follicular phase) 27–122
FSH (IU/L)	0.15	0.38	0.19	0.06	Male 1–8
					Female (follicular phase) 3.85–8.78
60 min FSH (IU/L)	0.51	Not detected	0.69	0.22
LH (IU/L)	0.04	0.07	0.1	0.02	Male 2–12
					Female (follicular phase) 2.12-10.89
60 min LH (IU/L)	0.06	Not detected	0.25	0.04
PRL (ng/mL)	19.75	22	16.99	18.46	Male 1.61-18.77
					Female 3.34-26.72
8:00 am serum cortisol (ug/dL)	<0.8∗	2.6	2.6	0.9	2.9–19.4
ACTH (pmol/L)	5.45	6.6	5.15	5.45	0-10.2
24-h UFC (μg/dL)	<0.8	<0.8	<0.8	<0.8	0.8–11.7
FT3 (pmol/L)	4.8	4.0	4.43	4.6	2.63–5.7
FT4 (pmol/L)	4.6	11	7.56	4.4	7.5–21
TSH (mIU/L)	1.76	2.36	2.92	5.94	0.3–5.95
Number of axes with hormone deficiencies	4	4	3	4
ALT (U/L)	26	15	14	36	1–40
AST (U/L)	34	27	30	37	1–37
TC (mmol/L)	6.7	5.5	4.6	5.4	3.1–5.2
TG (mmol/L)	1.93	0.6	0.64	2.4	0.33–1.7
LDL-C (mmol/L)	4.94	3.58	2.63	3.38	1.94–3.4
Uric acid (μmol/L)	596	325	374	443	200–420
NAFLD	Yes	No	No	Yes

Below detection value. Treatment with levothyroxine. BMI, body mass index; WHR, waist to hip ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; IGF-1, insulin-like growth factor-1; SDS: standard deviation score; FSH, follicle stimulating hormone; 60 min FSH, FSH was measured at 60 minutes following intramuscular injection triptorelin 100 ug; LH, luteinizing hormone; 60 min LH, LH was measured at 60 minutes following intramuscular injection triptorelin 100 ug; PRL, prolactin; ACTH, adrenocorticotropic hormone; 24-h UFC, 24-h urinary free cortisol; FT3, free triiodothyronine; FT4, free thyroxine; TSH, thyroid stimulating hormone; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TC, total cholesterol; TG, triglycerides; LDL-C, low-density lipoprotein-cholesterol; NAFLD, nonalcoholic fatty liver disease.